AI Article Synopsis
Article Abstract
Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciab086 | DOI Listing |
Publication Analysis
Top Keywords
participants dolutegravir
4
dolutegravir resuppress
4
resuppress human
4
human immunodeficiency
4
immunodeficiency virus
4
virus rna
4
rna virologic
4
virologic failure
4
failure updated
4
updated data
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!